Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ACAB) is a clinical-stage biopharmaceutical company that reached the public markets through a de-SPAC merger with Atlantic Coastal Acquisition Corp II, a blank-check vehicle that completed its initial public offering in 2022 and was sponsored by Atlantic Coastal Acquisition Corp II Sponsor LLC. The SPAC targeted the life sciences and biotechnology sector before combining with Abpro, an antibody engineering firm developing next-generation bispecific therapeutic candidates with a focus on oncology. The company filed a Form 10-Q with the SEC on November 26, 2024, reflecting its ongoing status as an active reporting public company post-merger. Sign up at SpacDesk for full filing history, deal timelines, and analytics on Abpro Holdings and the entire SPAC universe.